Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flucitrin
- Development stage
- Unknown
- Lead developer
- Abian Pharmed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flucitrin is a line of over-the-counter (OTC) cold and flu combination medications developed and marketed by the Iranian pharmaceutical company Abian Pharmed. It is available in two distinct formulations packaged as sachets for oral solution: Flucitrin Day and Flucitrin Night. Flucitrin Day contains acetaminophen (an analgesic and antipyretic), phenylephrine hydrochloride (a nasal decongestant), dextromethorphan hydrobromide (a cough suppressant), and ascorbic acid (Vitamin C). Flucitrin Night contains acetaminophen, phenylephrine hydrochloride, diphenhydramine hydrochloride (a sedating antihistamine), and ascorbic acid. Together, these formulations are used to relieve symptoms associated with the common cold, influenza, and sinusitis, including fever, body aches, headache, sore throat, nasal congestion, and coughing.
- Brand names
- FlucitrinFlucitrin DayFlucitrin Night
- Other names
- فلوسیترینفلوسیترین روزفلوسیترین شب
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)ADRA1A (α1A)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Flucitrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flucitrin.